Potential involvement of mineralocorticoid receptor activation in the pathogenesis of central serous chorioretinopathy: Case report

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 10, 2013, Pages 1369-1373

  Gruszka, A ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Central serous chorioretinopathy; Eplerenone; Mineralocorticoid receptors

Indexed keywords

EPLERENONE; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR;

ADULT; ARTICLE; BLURRED VISION; CASE REPORT; CENTRAL SEROUS RETINOPATHY; DISEASE COURSE; DRUG TOLERABILITY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTRAOCULAR PRESSURE; LASER COAGULATION; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; RECURRENT DISEASE; RETINA DETACHMENT; RETINA MACULA LUTEA; SUBRETINAL FLUID; VISUAL ACUITY;

ADULT; CENTRAL SEROUS CHORIORETINOPATHY; FEMALE; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, MINERALOCORTICOID;

EID: 84878536305     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. GEMENETZI M, DE SALVO G, LOTERY AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye 2010; 24: 1743-1756.
2. WANG M, MUNCH IC, HASLER PW, PRÜNTE C, LARSEN M. Central serous chorioretinopathy. Acta Ophthalmol 2008; 86: 126-145.
3. BOUZAS EA, KARADIMAS P, POURNARAS CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002; 47: 431-448.
4. LIEW G, QUIN G, GILLIES M, FRASER-BELL S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Experiment Ophthalmol 2013; 41: 201-214.
5. MCCURLEY A, JAFFE IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol 2012; 350: 256-265.
6. GOLESTANEH N, PICAUD S, MIRSHAHI M. The mineralocorticoid receptor in rodent retina: ontogeny and molecular identity. Mol Vis 2002; 8: 221-225.
7. WILKINSON-BERKA JL, TAN G, JAWORSKI K, MILLER AG. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res 2009; 104: 124-133.
8. ZHAO M, VALAMANESH F, CELERIER I, SAVOLDELLI M, JONET L, JEANNY JC, JAISSER F, FARMAN N, BEHAR-COHEN F. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Müller glial cells. FASEB J 2010; 24: 3405-3415.
9. ZHAO M, CÉLÉRIER I, BOUSQUET E, JEANNY JC, JONET L, SAVOLDELLI M, OFFRET O, CURAN A, FARMAN N, JAISSER F, BEHAR-COHEN F. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 2012; 122: 2672-2679.
10. HAIMOVICI R, RUMELT S, MELBY J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 2003; 110: 698-703.
11. ZAKIR SM, SHUKLA M, SIMI ZU, AHMAD J, SAJID M. Serum cortisol and testosterone levels in idiopathic central serous chorioretinopathy. Indian J Ophthalmol 2009; 57: 419-422.
12. CARVALHO-RECCHIA CA, YANNUZZI LA, NEGRÃO S, SPAIDE RF, FREUND KB, RODRIGUEZ-COLEMAN H, LENHARO M, IIDA T. Corticosteroids and central serous chorioretinopathy. Ophthalmology 2002; 109: 1834-1837.
13. MEYERLE CB, FREUND KB, BHATNAGAR P, SHAH V, YANNUZZI LA. Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina 2007; 27: 943-946.
14. GOLSHAHI A, KLINGMÜLLER D, HOLZ FG, ETER N. Ketoconazole in the treatment of central serous chorioretinopathy: a pilot study. Acta Ophthalmol 2010; 88: 576-581.
15. NIELSEN JS, JAMPOL LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina 2011; 31: 1928-1936.
16. WHITE PC, MUNE T, AGARWAL AK. 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev1997; 18: 135-156.
17. ODERMATT A, KRATSCHMAR DV. Tissue-specific modulation of mineralocorticoid receptor function by 11β-hydroxysteroid dehydrogenases: an overview. Mol Cell Endocrinol 2012; 350: 168-186.